IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer
Comparison
Peer Comparison Report
Performance
Performance Report
Supriya Lifescience
IPO is a MainBoard IPO coming on
BSE,NSE with an
IPO
size of
700.00 Cr.
.
This IPO falls under the
Pharmaceutical sector, which has seen
22 IPOs
to date. Key sector metrics such as average PE ratio, IPO size, EBITDA margin, and
PAT margin are compared below with the figures from the
Supriya Lifescience
IPO.
You can do performance analysis for Supriya Lifescience IPO with Listed IPOs in the Pharmaceutical sector and review their IPO performance based on Merchant banker, Listing price, IPO Valuation and other metrics.
This IPO report captures the post-listing performance of IPOs in the Pharmaceutical sector, featuring key metrics like offer price, listing gain, and CMP to help investors assess return potential and sector sentiment.
| NAME | OFFER PRICE | LISTING PRICE | LISTING GAIN | CMP | CMP % |
|---|---|---|---|---|---|
|
Senores Pharmaceuticals
IPO
Financial Report >> |
₹ 391.00 | ₹ 609.00 | 55.75% | ₹ 582.65 | 49% |
|
Akums Drugs
IPO
Financial Report >> |
₹ 679.00 | ₹ 796.35 | 17.28% | ₹ 576.00 | -15% |
|
Emcure Pharmaceuticals
IPO
Financial Report >> |
₹ 1008.00 | ₹ 1358.85 | 34.81% | ₹ 1281.60 | 27% |
|
Indegene Limited
IPO
Financial Report >> |
₹ 452.00 | ₹ 570.65 | 26.25% | ₹ 575.35 | 27% |
|
Innova Captab
IPO
Financial Report >> |
₹ 448.00 | ₹ 545.15 | 21.69% | ₹ 844.30 | 88% |
|
Blue Jet
IPO
Financial Report >> |
₹ 346.00 | ₹ 395.85 | 14.41% | ₹ 843.55 | 144% |
|
Valiant Laboratories
IPO
Financial Report >> |
₹ 140.00 | ₹ 169.05 | 20.75% | ₹ 113.20 | -19% |
|
Concord Biotech
IPO
Financial Report >> |
₹ 741.00 | ₹ 941.85 | 27.11% | ₹ 1795.30 | 142% |
|
Mankind Pharma
IPO
Financial Report >> |
₹ 1080.00 | ₹ 1424.05 | 31.86% | ₹ 2287.00 | 112% |
|
Supriya Lifescience
IPO
Financial Report >> |
[●] | ₹ 390.35 | 42.46% | ₹ 709.05 | 159% |
|
Medplus Health
IPO
Financial Report >> |
[●] | ₹ 1120.85 | 40.81% | ₹ 890.05 | 12% |
|
Windlas Biotech
IPO
Financial Report >> |
[●] | ₹ 406.70 | 406.70% | ₹ 890.75 | 94% |
|
Glenmark Life
IPO
Financial Report >> |
[●] | ₹ 748.20 | 748.20% | ₹ 998.50 | 39% |
|
Gland Pharma
IPO
Financial Report >> |
[●] | ₹ 1820.45 | 1820.45% | ₹ 1878.00 | 25% |
|
Eris Lifesciences
IPO
Financial Report >> |
[●] | ₹ 601.05 | 601.05% | ₹ 1676.60 | 178% |
|
Laurus Labs
IPO
Financial Report >> |
[●] | ₹ 480.50 | 480.50% | ₹ 746.05 | 772% |
|
Alkem Laboratories
IPO
Financial Report >> |
[●] | ₹ 1381.45 | 1381.45% | ₹ 4849.00 | 362% |
|
Syngene International
IPO
Financial Report >> |
[●] | ₹ 310.40 | 310.40% | ₹ 638.90 | 156% |
|
Brooks Laboratories
IPO
Financial Report >> |
[●] | ₹ 60.20 | -39.80% | ₹ 145.97 | 46% |
|
Parabolic Drugs
IPO
Financial Report >> |
[●] | ₹ 64.80 | 64.80% | [●] | [●] |
|
Bafna Pharmaceuticals
IPO
Financial Report >> |
[●] | ₹ 38.50 | 38.50% | [●] | [●] |
|
SMS Pharmaceuticals
IPO
Financial Report >> |
[●] | ₹ 357.85 | 357.85% | ₹ 250.70 | 560% |
Supriya Lifescience IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
The peers of
Supriya Lifescience ,
include other listed companies operating in the
(Pharmaceutical) segment. These peer companies typically
offer similar services Some of the notable peers as per the DRHP of this company
are
.
See the complete list of
current IPO
Peer Comparison is the method of evaluating an entity by comparing its performance, size of business form other entities operating in same industry or sector. It involves financial analysis by comparing key financial metrics like Profitability, Net worth, Market Capitalization and Leverage IPO Performance tracker
Peer comparison helps to identify companies in the same sector with a similar business. It helps to compare the financial performance and valuation against its listed peers. An investor or an analyst can decide whether the IPO price is justified when compared to its peers. An investor can make informed decision whether to apply to IPO or not on basis of peer comparison. Know the process of DRHP and Peer companies Information required to be disclosed in DRHP.
As of now 22 IPOs are listed in this sector indicating strong growth in this sector. Choosing the best IPO depends on factors like, financial performance, valuation, market trends and future growth plans. IPO Review and performance.
A good PE Ratio for Pharmaceutical sector depends on various factors like, performance of the company, market conditions, company valuation and IPO Size. PE Ratio varies from sector to sector and company to company. Know the average PE Multiple in each sector.
Currently 22 companies are listed under Pharmaceutical sector. Based on the latest data from the Stock Exchanges. Choose the Best Merchant Banker from the Merchant Banker List
Performance of companies depends on various factors like, profits, future plans, Market share, PE Ratio etc. By assessing these factors investor can make better investment decisions.Supriya Lifescience Peer comparison provides IPO analysis of companies listed in this sector, on the basis of different Key performance indicators (KPI)like, Listing Gain of peers, current market price, PE Ratio and IPO Size.
Upcoming IPO refers to companies which have filed their DRHP with the Stock exchange and are awaiting approval from NSE or BSE 14 companies have filed their DRHP for IPO under Pharmaceutical sector. .New IPO 2025-2026 and Upcoming IPO
PE Multiple is a metrics that is widely used for IPO Valuation. Merchant bankers in coordination with the company decides the PE Multiple.The PE Multiple depends on various factors and it should be analyzed in coordination with other financial metrics. Know the PE ratio of your company with PE Calculator provided by IPOplatform
Supriya Lifescience operates in Pharmaceutical and Manufacturers And Suppliers Of Active Pharmaceuticals. The Issue is listed on BSE,NSE in Dec, 2021. Supriya Lifescience IPO size was 700.00 with Issue price of 274.00 .
Merchant Banker(s) of Supriya Lifescience IPO: Axis Capital Limited , ICICI Securities Limited
Supriya Lifescience IPO subscription was 71.51 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Supriya Lifescience IPO listed at a listing price of 390.35 against the offer price of 274.00.
The current market price of Supriya Lifescience is 709.05.
Why Us?
